Evidence map›Paper›PMID 21464443›Full record

ArticleDiabetes2011

Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling.

Heather C Denroche, Jasna Levi, Rhonda D Wideman, Roveena M Sequeira, Frank K Huynh, Scott D Covey, Timothy J Kieffer

Open access · hybridAbstract read
In one paragraph

Article in Diabetes, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 124 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Obesity: An Impact with Cardiovascular and Cerebrovascular Diseases.Indian journal of clinical biochemistry : IJCB · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Leptin signaling and leptin resistance.Medical review (2021) · 2022
    Review
  13. Article
  14. Article
  15. The association between body composition, leptin levels and glucose dysregulation in youth with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Type 2 diabetes and viral infection; cause and effect of disease.Diabetes research and clinical practice · 2021
    Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Heather C DenrocheDepartment of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Jasna Levi
Rhonda D Wideman
Roveena M Sequeira
Frank K Huynh
Scott D Covey
Timothy J Kieffer
University of British Columbia · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

objectiveLeptin therapy has been found to reverse hyperglycemia and prevent mortality in several rodent models of type 1 diabetes. Yet the mechanism of leptin-mediated reversal of hyperglycemia has not been fully defined. The liver is a key organ regulating glucose metabolism and is also a target of leptin action. Thus we hypothesized that exogenous leptin administered to mice with streptozotocin (STZ)-induced diabetes reverses hyperglycemia through direct action on hepatocytes. RESEARCH DESIGN AND

methodsAfter the induction of diabetes in mice with a high dose of STZ, recombinant mouse leptin was delivered at a supraphysiological dose for 14 days by an osmotic pump implant. We characterized the effect of leptin administration in C57Bl/6J mice with STZ-induced diabetes and then examined whether leptin therapy could reverse STZ-induced hyperglycemia in mice in which hepatic leptin signaling was specifically disrupted.

resultsHyperleptinemia reversed hyperglycemia and hyperketonemia in diabetic C57Bl/6J mice and dramatically improved glucose tolerance. These effects were associated with reduced plasma glucagon and growth hormone levels and dramatically enhanced insulin sensitivity, without changes in glucose uptake by skeletal muscle. Leptin therapy also ameliorated STZ-induced hyperglycemia and hyperketonemia in mice with disrupted hepatic leptin signaling to a similar extent as observed in wild-type littermates with STZ-induced diabetes.

conclusionsThese observations reveal that hyperleptinemia reverses the symptoms of STZ-induced diabetes in mice and that this action does not require direct leptin signaling in the liver.

Indexed as

AnimalsBlood GlucoseDiabetes Mellitus, ExperimentalEnzyme-Linked Immunosorbent AssayGlucagonGrowth HormoneHyperglycemiaLeptinLiverMaleMiceMice, Inbred C57BLPostprandial PeriodReceptors, LeptinReverse Transcriptase Polymerase Chain ReactionSignal TransductionBlood GlucoseGlucagonGrowth HormoneLeptinReceptors, Leptin

Identifiers

PMID21464443
PMCPMC3292314
OpenAlexW2163226222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.